Comorbidities and Malignancy among NAFLD Patients Compared to the General Population, A Nation-Based Study.
Israel
comorbidities
fatty liver
malignancy
mortality
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
06 Apr 2023
06 Apr 2023
Historique:
received:
16
03
2023
revised:
31
03
2023
accepted:
04
04
2023
medline:
16
5
2023
pubmed:
16
5
2023
entrez:
16
5
2023
Statut:
epublish
Résumé
(1) Background: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease. Aims: We aimed to investigate the frequency of comorbidities and malignancies among NAFLD patients compared to the general population. (2) Methods: A retrospective study included adult patients with a NAFLD diagnosis. A control group was matched for age and gender. Demographics, comorbidities, malignancies, and mortality were collected and compared. (3) Results: 211,955 NAFLD patients were analyzed in comparison to 452,012 matched general population controls. Significantly higher rates of diabetes mellitus (23.2% vs. 13.3%), obesity (58.8% vs. 27.8%), hypertension (57.2% vs. 39.9%), chronic ischemic heart disease (24.7% vs. 17.3%), and CVA (3.2% vs. 2.8%) were found among NAFLD patients. Patients with NAFLD had significantly higher rates of the following malignancies: prostate cancer (1.6% vs. 1.2%), breast cancer (2.6% vs. 1.9%), colorectal cancer (1.8% vs. 1.4%), uterine cancer (0.4 vs. 0.2%), kidney cancer (0.8% vs. 0.5%), but a lower rate of lung cancer (0.9% vs. 1.2%) and stomach cancer (0.3% vs. 0.4%). The all-cause mortality rate among NAFLD patients was significantly lower in comparison to the general population (10.8% vs. 14.7%,
Identifiants
pubmed: 37189727
pii: biomedicines11041110
doi: 10.3390/biomedicines11041110
pmc: PMC10136025
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cell Metab. 2017 May 2;25(5):1054-1062.e5
pubmed: 28467925
Am J Clin Nutr. 2014 Apr;99(4):804-12
pubmed: 24522441
Clin Gastroenterol Hepatol. 2020 Jul;18(8):1887-1889
pubmed: 31404663
Cell Metab. 2020 Nov 3;32(5):878-888.e6
pubmed: 32610095
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Nutrients. 2021 Nov 23;13(12):
pubmed: 34959747
BMC Gastroenterol. 2014 Sep 27;14:166
pubmed: 25260964
Nephrol Dial Transplant. 2019 Mar 1;34(3):449-457
pubmed: 29390103
Presse Med. 2019 Dec;48(12):1459-1467
pubmed: 31757728
Dtsch Arztebl Int. 2020 Oct 23;117(43):719-724
pubmed: 33559592
PLoS One. 2017 Mar 27;12(3):e0173499
pubmed: 28346543
Sci Rep. 2019 Jul 31;9(1):11124
pubmed: 31366982
Gut. 2021 Jul;70(7):1375-1382
pubmed: 33037056
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Rev Gastroenterol Hepatol. 2020 May;17(5):279-297
pubmed: 32152478
Diabetol Metab Syndr. 2018 Jan 24;10:4
pubmed: 29410708
J Hepatol. 2019 Dec;71(6):1229-1236
pubmed: 31470068
Front Nutr. 2023 Feb 16;10:1110536
pubmed: 36875849
Diagnostics (Basel). 2021 Apr 12;11(4):
pubmed: 33921359
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Nutrients. 2019 Oct 22;11(10):
pubmed: 31652512
J Hepatol. 2016 Sep;65(3):589-600
pubmed: 27212244
Diabetologia. 2018 Oct;61(10):2140-2154
pubmed: 30027404
JAMA. 2020 Mar 24;323(12):1175-1183
pubmed: 32207804
Liver Int. 2018 Feb;38 Suppl 1:47-51
pubmed: 29427488
Biomedicines. 2020 Jan 07;8(1):
pubmed: 31936158
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Hepatobiliary Pancreat Dis Int. 2017 Aug 15;16(4):375-381
pubmed: 28823367
Gastroenterology. 2020 May;158(7):1929-1947.e6
pubmed: 32068022
Clin Mol Hepatol. 2023 Feb;29(Suppl):s86-s102
pubmed: 36603574
BMJ. 2011 Nov 18;343:d6891
pubmed: 22102439
Nutrients. 2022 Aug 03;14(15):
pubmed: 35956364
Nutrients. 2022 Sep 14;14(18):
pubmed: 36145163
Am J Clin Nutr. 2012 Oct;96(4):727-34
pubmed: 22952180
Diabetes Care. 2020 May;43(5):1134-1141
pubmed: 32165444
Gut. 2022 Sep;71(9):1867-1875
pubmed: 34489307
Metabolism. 2018 Feb;79:64-76
pubmed: 29137912
Dig Dis Sci. 2020 Jul;65(7):2112-2119
pubmed: 31797186